The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
Open accessAbstract
BACKGROUND: Identification of residual disease in patients with localized non-small cell lung cancer (NSCLC) following treatment with curative intent holds promise to identify patients at risk of relapse. New methods can detect circulating tumour DNA (ctDNA) in plasma to fractional concentrations as low as a few parts per million, and clinical evidence is required to inform their use. PATIENTS AND METHODS: We analyzed 363 serial plasma samples from 88 patients with early-stage NSCLC (48.9%/28.4%/22.7% at stage I/II/III), predominantly adenocarcinomas (62.5%), treated with curative intent by surgery (n = 61), surgery and adjuvant chemotherapy/radiotherapy (n = 8), or chemoradiotherapy (n = 19). Tumour exome sequencing identified somatic mutations and plasma was analyzed using patient-specific RaDaR™ assays with up to 48 amplicons targeting tumour-specific variants unique to each patient. RESULTS: ctDNA was detected before treatment in 24%, 77% and 87% of patients with stage I, II and III disease, respectively, and in 26% of all longitudinal samples. The median tumour fraction detected was 0.042%, with 63% of samples <0.1% and 36% of samples <0.01%. ctDNA detection had clinical specificity >98.5% and preceded clinical detection of recurrence of the primary tumour by a median of 212.5 days. ctDNA was detected after treatment in 18/28 (64.3%) of patients who had clinical recurrence of their primary tumour. Detection within the landmark timepoint 2 weeks to 4 months after treatment end occurred in 17% of patients, and was associated with shorter recurrence-free survival [hazard ratio (HR): 14.8, P <0.00001] and overall survival (HR: 5.48, P <0.0003). ctDNA was detected 1-3 days after surgery in 25% of patients yet was not associated with disease recurrence. Detection before treatment was associated with shorter overall survival and recurrence-free survival (HR: 2.97 and 3.14, P values 0.01 and 0.003, respectively). CONCLUSIONS: ctDNA detection after initial treatment of patients with early-stage NSCLC using sensitive patient-specific assays has potential to identify patients who may benefit from further therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
Li, H. (2013) · DROPS (Schloss Dagstuhl – Leibniz Center for Informatics) · doi:10.48550/arxiv.1303.3997 · Cited by 5,159
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Haplotype-based variant detection from short-read sequencing
Garrison, E., & Marth, G. (2012) · arXiv · doi:10.48550/arxiv.1207.3907 · Cited by 3,700
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · cited 2×
“Such improvements have enabled rapid advancement of ctDNA as a liquid biopsy for clinical applications, where it is now being investigated or implemented for cancer diagnosis, to guide treatment selection, to monitor therapeutic response and to identify newly emerging resistance mutations.(4) With the development of h…”
BackgroundSelf-citationCirculating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207 · cited 2×
“Subsequent studies utilized next-generation sequencing (NGS) to monitor multiple mutations in parallel.(5,9-11) Sensitivity for ctDNA detection can be increased by error suppression techniques, analysis of a larger number of somatic variants or larger volume of blood.”
BackgroundSelf-citationPhylogenetic ctDNA analysis depicts early-stage lung cancer evolution
The TRACERx consortium, Abbosh, C., The PEACE consortium, Birkbak, N. J., Wilson, G. A., Jamal-Hanjani, M., Constantin, T., Salari, R., Le Quesne, J., Moore, D. A., et al. (2017) · Nature · doi:10.1038/nature22364 · Cited by 1,874
Vogelstein, B., & Kinzler, K. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9236 · Cited by 1,770 · cited 2×
“Initial studies analyzed individual somatic mutations that were common to specific cancer types, using methods such as digital PCR and BEAMing.7,8 Subsequent studies utilized next-generation sequencing (NGS) to monitor multiple mutations in parallel.5,9-11 Sensitivity for ctDNA detection can be increased by error supp…”
MethodInfluentialNon-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · cited 1×
“Subsequent studies utilized next-generation sequencing (NGS) to monitor multiple mutations in parallel.(5,9-11) Sensitivity for ctDNA detection can be increased by error suppression techniques, analysis of a larger number of somatic variants or larger volume of blood.”
BackgroundSelf-citationTie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., Silliman, N., Tacey, M., Wong, H.-L., Christie, M., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6219 · Cited by 1,492
Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F., Dawson, S.-J., Piskorz, A. M., Jimenez-Linan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,297
Self-citationMutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Garcia-Murillas, I., Schiavon, G., Weigelt, B., Ng, C., Hrebien, S., Cutts, R. J., Cheang, M., Osin, P., Nerurkar, A., Kozarewa, I., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab0021 · Cited by 1,150
Detection and quantification of rare mutations with massively parallel sequencing
Kinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W., & Vogelstein, B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105422108 · Cited by 1,144
Integrated digital error suppression for improved detection of circulating tumor DNA
Newman, A. M., Lovejoy, A. F., Klass, D. M., Kurtz, D. M., Chabon, J. J., Scherer, F., Stehr, H., Liu, C. L., Bratman, S. V., Say, C., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3520 · Cited by 1,099
Chaudhuri, A. A., Chabon, J. J., Lovejoy, A. F., Newman, A. M., Stehr, H., Azad, T. D., Khodadoust, M. S., Esfahani, M. S., Liu, C. L., Zhou, L., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0716 · Cited by 1,072
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
Lai, Z., Markovets, A., Ahdesmaki, M., Chapman, B., Hofmann, O., McEwen, R., Johnson, J., Dougherty, B., Barrett, J. C., & Dry, J. R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw227 · Cited by 970
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Powles, T., Assaf, Z. J., Davarpanah, N., Banchereau, R., Szabados, B. E., Yuen, K. C., Grivas, P., Hussain, M., Oudard, S., Gschwend, J. E., et al. (2021) · Nature · doi:10.1038/s41586-021-03642-9 · Cited by 646
Murtaza, M., Dawson, S.-J., Pogrebniak, K., Rueda, O. M., Provenzano, E., Grant, J., Chin, S.-F., Tsui, D. W. Y., Marass, F., Gale, D., et al. (2015) · Nature Communications · doi:10.1038/ncomms9760 · Cited by 483
Self-citationGenome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
Zviran, A., Schulman, R. C., Shah, M., Hill, S. T. K., Deochand, S., Khamnei, C. C., Maloney, D., Patel, K., Liao, W., Widman, A. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0915-3 · Cited by 434
Kurtz, D. M., Soo, J., Co Ting Keh, L., Alig, S., Chabon, J. J., Sworder, B. J., Schultz, A., Jin, M. C., Scherer, F., Garofalo, A., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-00981-w · Cited by 374
Moding, E. J., Liu, Y., Nabet, B. Y., Chabon, J. J., Chaudhuri, A. A., Hui, A. B., Bonilla, R. F., Ko, R. B., Yoo, C. H., Gojenola, L., et al. (2020) · Nature Cancer · doi:10.1038/s43018-019-0011-0 · Cited by 365
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0634 · Cited by 325 · cited 2×
“With the development of highly-sensitive patientspecific assays, ctDNA has been used to detect MRD in patients with breast, colorectal, lung cancer and other solid tumours.(16,19-26) In NSCLC, Chaudhuri et al.”
MethodResultMcDonald, B. R., Contente-Cuomo, T., Sammut, S.-J., Odenheimer-Bergman, A., Ernst, B., Perdigones, N., Chin, S.-F., Farooq, M., Mejia, R., Cronin, P. A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7392 · Cited by 305
Parkinson, C. A., Gale, D., Piskorz, A. M., Biggs, H., Hodgkin, C., Addley, H., Freeman, S., Moyle, P., Sala, E., Sayal, K., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002198 · Cited by 297
Self-citationAzad, T. D., Chaudhuri, A. A., Fang, P., Qiao, Y., Esfahani, M. S., Chabon, J. J., Hamilton, E. G., Yang, Y. D., Lovejoy, A., Newman, A. M., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.10.039 · Cited by 266
Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)
Chen, K., Zhao, H., Shi, Y., Yang, F., Wang, L. T., Kang, G., Nie, Y., & Wang, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1213 · Cited by 239
Self-citationctDNA monitoring using patient-specific sequencing and integration of variant reads
Wan, J. C. M., Heider, K., Gale, D., Murphy, S., Fisher, E., Mouliere, F., Ruiz-Valdepenas, A., Santonja, A., Morris, J., Chandrananda, D., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8084 · Cited by 194
Self-citationSensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer
Parsons, H. A., Rhoades, J., Reed, S. C., Gydush, G., Ram, P., Exman, P., Xiong, K., Lo, C. C., Li, T., Fleharty, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3005 · Cited by 193
Gale, D., Lawson, A. R. J., Howarth, K., Madi, M., Durham, B., Smalley, S., Calaway, J., Blais, S., Jones, G., Clark, J., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194630 · Cited by 172
Self-citationPlagnol, V., Woodhouse, S., Howarth, K., Lensing, S. V., Smith, M. J., Epstein, M., Madi, M., Smalley, S., Leroy, C., Hinton, J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193802 · Cited by 99
Self-citationClonal haematopoiesis: a source of biological noise in cell-free DNA analyses
Abbosh, C., Swanton, C., & Birkbak, N. J. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy552 · Cited by 92
Liquid biopsies for residual disease and recurrence
Wan, J. C. M., Mughal, T. I., Razavi, P., Dawson, S., Moss, E. L., Govindan, R., Tan, I. B., Yap, Y. S., Robinson, W. A., Morris, C. D., et al. (2021) · Med · doi:10.1016/j.medj.2021.11.001 · Cited by 50
Self-citationUtilizing circulating tumour DNA in radiation oncology
Rostami, A., & Bratman, S. V. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.07.004 · Cited by 26
ctDNA detection by personalised assays in early-stage NSCLCPreprint
Heider, K., Wan, J. C. M., Gale, D. G., Ruiz-Valdepeñas, A., Mouliere, F. C., Morris, J., Qureshi, N. R., Qian, W., Knock, H., Wulff, J., et al. (2021) · medRxiv · doi:10.1101/2021.06.01.21258171 · Cited by 4
Self-citation
Cited by
Embracing cancer complexity: Hallmarks of systemic disease
Swanton, C., Bernard, E., Abbosh, C., André, F., Auwerx, J., Balmain, A., Bar-Sagi, D., Bernards, R., Bullman, S., DeGregori, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.02.009 · Cited by 540
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Abbosh, C., Frankell, A. M., Harrison, T., Kisistok, J., Garnett, A., Johnson, L., Veeriah, S., Moreau, M., Chesh, A., Chaunzwa, T. L., et al. (2023) · Nature · doi:10.1038/s41586-023-05776-4 · Cited by 382
Lipsyc-Sharf, M., de Bruin, E. C., Santos, K., McEwen, R., Stetson, D., Patel, A., Kirkner, G. J., Hughes, M. E., Tolaney, S. M., Partridge, A. H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00908 · Cited by 152
“Formalin-fixed paraffin-embedded tissue block and Hematoxylin & Eosin slide (or 10-20 unstained slides and Hematoxylin & Eosin slide) were sent to Inivata Inc (Durham, NC) where DNA was extracted and whole-exome sequencing (WES) performed as previously described.(24,25) Detection of somatic mutations was used to desig…”
MethodSelf-citationMinimal residual disease as a target for liquid biopsy in patients with solid tumours
Pantel, K., & Alix-Panabières, C. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00967-y · Cited by 146
Circulating Tumor DNA—A Novel Biomarker of Tumor Progression and Its Favorable Detection Techniques
Wen, X., Pu, H., Liu, Q., Guo, Z., & Luo, D. (2022) · Cancers · doi:10.3390/cancers14246025 · Cited by 99
Metadata
- Authors
- Gale, D., Heider, K., Ruiz-Valdepenas, A., Hackinger, S., Perry, M., Marsico, G., Rundell, V., Wulff, J., Sharma, G., Knock, H., Castedo, J., Cooper, W., Zhao, H., Smith, C. G., Garg, S., Anand, S., Howarth, K., Gilligan, D., Harden, S. V., Rassl, D. M., Rintoul, R. C., & Rosenfeld, N.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2022-05
- Volume
- 33
- Issue
- 5
- Pages
- 500-510
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4221017231
- Cited by
- 335
- References
- 34
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.